J-L. Canon

566 total citations
29 papers, 406 citations indexed

About

J-L. Canon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J-L. Canon has authored 29 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in J-L. Canon's work include Cancer Treatment and Pharmacology (8 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (6 papers). J-L. Canon is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (6 papers). J-L. Canon collaborates with scholars based in Belgium, France and United States. J-L. Canon's co-authors include Lionel Duck, Joseph Kerger, J-P. Machiels, Nicolas Janus, Hans Wildiers, Willem Lybaert, Vincent Launay‐Vacher, Joëlle Nortier, Wim Wynendaele and Yves Humblet and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

J-L. Canon

27 papers receiving 397 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J-L. Canon Belgium	9	264	119	109	47	41	29	406
Cem Mirili Türkiye	9	212 0.8×	80 0.7×	45 0.4×	28 0.6×	32 0.8×	21	293
Fahriye Tuğba Köş Türkiye	10	182 0.7×	77 0.6×	50 0.5×	26 0.6×	30 0.7×	40	274
Deborah Malvi Italy	13	127 0.5×	147 1.2×	178 1.6×	26 0.6×	31 0.8×	54	504
Katrin Hefler‐Frischmuth Austria	11	204 0.8×	118 1.0×	71 0.7×	22 0.5×	11 0.3×	17	479
Shane Y. Morita United States	9	231 0.9×	84 0.7×	151 1.4×	71 1.5×	31 0.8×	22	503
Richard Lizambri United States	10	179 0.7×	320 2.7×	50 0.5×	20 0.4×	53 1.3×	16	521
Yuki Imaoka Japan	10	167 0.6×	103 0.9×	178 1.6×	12 0.3×	19 0.5×	87	415
Keiko Ohkuwa Japan	18	137 0.5×	79 0.7×	527 4.8×	36 0.8×	53 1.3×	46	1.1k
N. Finkler United States	13	197 0.7×	166 1.4×	224 2.1×	14 0.3×	92 2.2×	30	713
Daisuke Korenaga Japan	12	137 0.5×	245 2.1×	194 1.8×	15 0.3×	60 1.5×	30	445

Countries citing papers authored by J-L. Canon

Since Specialization

Citations

This map shows the geographic impact of J-L. Canon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J-L. Canon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J-L. Canon more than expected).

Fields of papers citing papers by J-L. Canon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J-L. Canon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J-L. Canon. The network helps show where J-L. Canon may publish in the future.

Co-authorship network of co-authors of J-L. Canon

This figure shows the co-authorship network connecting the top 25 collaborators of J-L. Canon. A scholar is included among the top collaborators of J-L. Canon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J-L. Canon. J-L. Canon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Agostinetto, Elisa, J-L. Canon, Florence Coussy, et al.. (2025). 192MO Primary endpoint of ROSALINE: A phase II neoadjuvant study of endocrine therapy (ET) and entrectinib in invasive lobular breast carcinoma (ILBC). ESMO Open. 10. 104746–104746.

Aftimos, Philippe, Kevin Punie, Lore Decoster, et al.. (2023). 181P GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative. Annals of Oncology. 34. S253–S254.

Decoster, Lore, Philippe Aftimos, Sylvie Rottey, et al.. (2023). 201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study. Annals of Oncology. 34. S262–S262. 1 indexed citations

Duhoux, François P., Nuhad K. Ibrahim, J-L. Canon, et al.. (2023). 255TiP AIPAC-003: A randomized, double-blind, placebo-controlled phase III trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization. ESMO Open. 8(1). 101443–101443. 1 indexed citations

Buisseret, Laurence, Delphine Loirat, Kevin Punie, et al.. (2022). LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC). Annals of Oncology. 33. S1385–S1385. 7 indexed citations

Joris, Sofie, Hannelore Denys, Daphné t’Kint de Roodenbeke, et al.. (2021). 88P Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision phase II basket study. Annals of Oncology. 32. S394–S394. 1 indexed citations

Bachelot, Thomas, Florence Dalenc, Sylvie Chabaud, et al.. (2021). Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer. Annals of Oncology. 32(4). 574–575. 8 indexed citations

Eiger, Daniel, Christian Maurer, Mariana Brandão, et al.. (2020). 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC). Annals of Oncology. 31. S386–S387. 8 indexed citations

Cottu, P., Véronique D’Hondt, Sylvain Dureau, et al.. (2017). Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study. Annals of Oncology. 28. v605–v605. 35 indexed citations

10.

Damaraju, Sambasivarao, Karen A. Gelmon, José Á. García-Sáenz, et al.. (2016). Abstract P1-13-03: Genome wide association study (GWAS) of genetic variants associated with docetaxel toxicity in the ROSE/TRIO-012 trial. Cancer Research. 76(4_Supplement). P1–13. 1 indexed citations

11.

Carrasco, Javier, Pierre Lefesvre, Catherine Hubert, et al.. (2015). Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. British Journal of Cancer. 113(9). 1298–1304. 15 indexed citations

12.

Canon, J-L., Jonas Bergh, Cristina Saura, et al.. (2012). Abstract OT2-3-02: Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase Ib preliminary data.. Cancer Research. 72(24_Supplement). OT2–3. 3 indexed citations

13.

Janus, Nicolas, Vincent Launay‐Vacher, J-P. Machiels, et al.. (2010). Cancer and renal insufficiency results of the BIRMA study. British Journal of Cancer. 103(12). 1815–1821. 133 indexed citations

14.

Decoster, Lore, Isabelle Vande Broek, Ellen Anckaert, et al.. (2010). ACTIVITY OF SUNITINIB IN ADVANCED SOFT TISSUE SARCOMA AND ITS CORRELATION WITH POTENTIAL PREDICTIVE BIOMARKERS. VUBIR (Vrije Universiteit Brussel). 21. 413–413. 1 indexed citations

15.

Cardoso, Fátima, J-L. Canon, D. Amadori, et al.. (2009). Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer : Abstract #4120. Cancer Research. 69(2). 1 indexed citations

16.

Machiels, J-P., Christine Sempoux, Pierre Scalliet, et al.. (2007). Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Annals of Oncology. 18(4). 738–744. 118 indexed citations

17.

Valero, Vicente, Hoffmann-La Roche, Tadeusz Pieńkowski, et al.. (2007). BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer. Journal of Clinical Oncology. 25(18_suppl). 1020–1020. 5 indexed citations

18.

Bosquée, Leon, Denis Schallier, Philippe Collard, et al.. (2006). Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. European Respiratory Journal. 29(1). 128–133. 12 indexed citations

19.

Bosly, André, Augustin Ferrant, Anne Sonet, et al.. (1995). 2-Chlorodeoxyadenosine in refractory non-Hodgkin's lymphoma: A phase II study on 50 patients.. Blood. 86(10). 212–212. 4 indexed citations

20.

Maerevoet, Marie, Augustin Ferrant, André Delannoy, et al.. (1995). 2-Chlorodeoxyadenosine (CDA) therapy in chronic lymphocytic leukemia (CLL) and Waldenstrom's macroglobulinemia (WD): An update on 77 patients.. Blood. 86(10). 3338–3338. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact